Medicare Enrolled
Dr. Walailuk Chaiyarat, MD
Hematology & Oncology · Concord, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chaiyarat from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chaiyarat?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chaiyarat
Dr. Walailuk Chaiyarat is a hematology & oncology specialist in Concord, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Chaiyarat performed 82,370 Medicare services across 1,631 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chaiyarat received a total of $16,099 from 72 pharmaceutical and/or device companies across 768 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chaiyarat is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 9% volume in CA
$16,099 industry payments
Medicare Practice Summary
Medicare Utilization ↗82,370
Medicare services
Top 9% in CA for hematology & oncology
1,631
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,845 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
33,150 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 20,600 | $38 | $111 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,850 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 7,440 | $18 | $53 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,821 | $6 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,234 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,100 | $1 | $99 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,090 | $113 | $305 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
424 | $13 | $75 |
| Anti-nausea injection (ondansetron/Zofran) | 384 | $0 | $2 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
267 | $70 | $210 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
255 | $13 | $64 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
244 | $15 | $79 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
235 | $2 | $9 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
233 | $163 | $406 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
224 | $133 | $514 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
218 | $30 | $113 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
217 | $71 | $222 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
204 | $65 | $244 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
188 | $33 | $197 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
100 | $1 | $14 |
| Albumin infusion, 25%, 50 ml Administration of a 50 ml intravenous infusion of 25% human albumin solution. |
86 | $42 | $200 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
83 | $25 | $90 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
76 | $28 | $108 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
72 | $20 | $80 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
71 | $1 | $15 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
64 | $1 | $4 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
62 | $68 | $251 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
58 | $107 | $347 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
53 | $37 | $190 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
45 | $8 | $15 |
| Hydromorphone injection, up to 4 mg An injection of hydromorphone, an opioid pain medication, with a dosage of up to 4 milligrams. |
43 | $3 | $13 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
41 | $117 | $412 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
27 | $94 | $308 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
27 | $142 | $461 |
| Injection, lorazepam, 2 mg | 20 | $1 | $4 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
17 | $37 | $210 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
17 | $80 | $305 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
15 | $162 | $768 |
| New patient office visit, complex (60-74 min) | 15 | $192 | $569 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
41.9% high complexity
55.2% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,099
Total received (2018-2024)
Avg $2,300/year across 7 years
Top 25% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
72
Companies
768
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,378 (95.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$720 (4.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,500
2023
$4,258
2022
$2,268
2021
$357
2020
$891
2019
$2,851
2018
$2,974
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$246
Merck Sharp & Dohme LLC
$236
Novartis Pharmaceuticals Corporation
$180
PFIZER INC.
$160
Janssen Biotech, Inc.
$159
ABBVIE INC.
$149
Takeda Pharmaceuticals U.S.A., Inc.
$141
E.R. Squibb & Sons, L.L.C.
$139
SpringWorks Therapeutics, Inc.
$110
ARRAY BIOPHARMA INC
$96
Daiichi Sankyo Inc.
$96
Celgene Corporation
$96
GlaxoSmithKline, LLC.
$94
Genmab U.S., Inc.
$85
Agios Pharmaceuticals, Inc.
$75
Stemline Therapeutics Inc.
$71
Lilly USA, LLC
$59
Janssen Pharmaceuticals, Inc
$32
Mirati Therapeutics, Inc.
$28
BeiGene USA, Inc.
$26
Alexion Pharmaceuticals, Inc.
$26
MorphoSys, US Inc.
$25
Astellas Pharma US Inc
$22
PharmaEssentia USA Corporation
$21
EMD Serono, Inc.
$21
SERVIER PHARMACEUTICALS LLC
$20
Eisai Inc.
$20
Incyte Corporation
$19
Edwards Lifesciences Corporation
$19
Gilead Sciences, Inc.
$15
RECORDATI_RARE_DISEASES_INC.
$15
Top 3 companies account for 26.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,273
PFIZER INC.
$1,169
E.R. Squibb & Sons, L.L.C.
$855
Amgen Inc.
$822
Merck Sharp & Dohme LLC
$763
Celgene Corporation
$723
Takeda Pharmaceuticals U.S.A., Inc.
$711
AstraZeneca Pharmaceuticals LP
$685
GlaxoSmithKline, LLC.
$630
Merck Sharp & Dohme Corporation
$588
Genentech USA, Inc.
$545
Lilly USA, LLC
$462
Astellas Pharma US Inc
$444
Janssen Biotech, Inc.
$415
Seagen Inc.
$411
Pharmacyclics LLC, An AbbVie Company
$372
GENZYME CORPORATION
$367
TESARO, Inc.
$351
Incyte Corporation
$336
ARRAY BIOPHARMA INC
$273
Myriad Genetic Laboratories, Inc.
$205
Daiichi Sankyo Inc.
$194
Boehringer Ingelheim Pharmaceuticals, Inc.
$182
SANOFI-AVENTIS U.S. LLC
$180
Exelixis Inc.
$169
Bayer HealthCare Pharmaceuticals Inc.
$163
ABBVIE INC.
$149
Eisai Inc.
$147
Sunovion Pharmaceuticals Inc.
$129
Stemline Therapeutics Inc.
$127
Gilead Sciences, Inc.
$122
Regeneron Healthcare Solutions, Inc.
$113
SpringWorks Therapeutics, Inc.
$110
Agios Pharmaceuticals, Inc.
$108
Janssen Pharmaceuticals, Inc
$102
AbbVie Inc.
$102
Clovis Oncology, Inc.
$100
Mirati Therapeutics, Inc.
$98
TAIHO ONCOLOGY, INC.
$85
Genmab U.S., Inc.
$85
Pharmacyclics LLC, an AbbVie Company
$83
SERVIER PHARMACEUTICALS LLC
$79
Kite Pharma, Inc.
$78
Alexion Pharmaceuticals, Inc.
$78
Foundation Medicine, Inc.
$68
BeiGene USA, Inc.
$65
EISAI INC.
$64
EMD Serono, Inc.
$61
Dendreon Pharmaceuticals LLC
$60
SOBI, INC
$52
Edwards Lifesciences Corporation
$51
AVEO Pharmaceuticals, Inc.
$50
G1 Therapeutics, Inc.
$40
Spectrum Pharmaceuticals Inc.
$35
CTI BioPharma Corp.
$30
MEDIVATION FIELD SOLUTIONS LLC
$27
Myovant Sciences Inc.
$26
MorphoSys, US Inc.
$25
Puma Biotechnology, Inc.
$24
Taiho Oncology, Inc.
$23
Fortovia Therapeutics, Inc.
$22
Sobi, Inc
$21
Kyowa Kirin, Inc.
$21
PharmaEssentia USA Corporation
$21
Heron Therapeutics, Inc.
$20
Array BioPharma Inc.
$20
EUSA Pharma (US) LLC
$18
Deciphera Pharmaceuticals Inc.
$18
Octapharma USA, Inc.
$16
RECORDATI_RARE_DISEASES_INC.
$15
AMAG Pharmaceuticals, Inc.
$13
Emmaus Medical, Inc.
$9
Top 3 companies account for 20.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AUGTYRO · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BAVENCIO · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CERDELGA · CINVANTI · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ELITEK · EMPLICITI · EPKINLY · ERBITUX · ERLEADA · EVENITY · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · Endari · Enhertu · Epkinly · FASENRA · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idhifa · Imbruvica · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONHALA MAGNAIR · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PANHEMATIN · PEMAZYRE · PIQRAY · POTELIGEO · PRECISETUMOR · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · Sylvant · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TRELEGY ELLIPTA · TUKYSA · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XOSPATA · XTANDI · Xofigo · Xospata · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
86
Per 100K population
7.4
County median income
$125,727
Nearest hospital
JOHN MUIR MEDICAL CENTER - CONCORD CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chaiyarat is a mixed practice specialist, with above-average Medicare volume (top 9% in CA), with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chaiyarat experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Chaiyarat performed 33,150 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chaiyarat receive payments from pharmaceutical companies?
Yes. Dr. Chaiyarat received a total of $16,099 from 72 companies across 768 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chaiyarat's costs compare to other hematology & oncology specialists in Concord?
Dr. Chaiyarat's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chaiyarat) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Concord
Browse hematology & oncology specialists in Concord ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology